US biotech company Biogen (Nasdaq: BIIB) beat analysts’ expectations with its first-quarter 2023 financial results, exceeding forecasts with both sales and earnings figures.
The Boston-based firm recorded quarterly revenue of $2.46 billion, down 3% on a year ago but ahead of the Wall Street consensus estimate of $2.34 billion. Earnings per share dropped by 6% to $3.40, but again above the analyst estimate of $3.28.
"We continued to make strong progress against our business priorities, most importantly execution of three potential launches in 2023"Biogen reaffirmed its 2023 guidance, which is for a mid-single digit percentage decline in revenue versus 2022, and earnings per share of between $15 and $16.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze